The University of Pittsburgh receives $1 million from The Giorgio Foundation to establish an endowed chair for ...

A new report describes a promising approach to studying neurofibromatosis type 1 (NF1), a genetic condition ... The organoids mimic the characteristics of the tumor they originated from.

assessing the efficacy and safety of oral Koselugo for treating adults with neurofibromatosis type 1 (NF1) with symptomatic inoperable plexiform neurofibromas (PN). The randomised, global ...

This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib.